Yicheng Guo

Dec 5, 2024 | biorxiv.org | Qian Wang |Yicheng Guo |Ryan G. Casner |Jian Yu

AbstractSARS-CoV-2 has largely evolved to resist antibody pressure, with each successive viral variant becoming more and more resistant to serum antibodies in the population. This evolution has rendered inactive all therapeutic monoclonal antibodies previously authorized, and it is now threatening the remaining clinical product for immunoprophylaxis against COVID-19.

Oct 23, 2024 | nature.com | Laty G. Thiam |Yicheng Guo |Saurabh Patel |Lawrence Shapiro |Simon Draper

AbstractVaccines to the Plasmodium falciparum reticulocyte binding-like protein homologue 5 (PfRH5) target the blood-stage of the parasite life cycle. PfRH5 has the potential to trigger the production of strain-transcendent antibodies and has proven its efficacy both in pre-clinical and early clinical studies. Vaccine-induced monoclonal antibodies (mAbs) to PfRH5 showed promising outcomes against cultured P. falciparum laboratory strains from distinct geographic areas.

May 29, 2024 | digitalcommons.library.tmc.edu | Qian Wang |Yicheng Guo |Sho Iketani |Manoj Nair

Home > UTHealth > McGovern Medical School > Journal Articles > 799 Antibodies, Neutralizing, Antibodies, Viral, Antigenic Drift and Shift, COVID-19, COVID-19 Vaccines, Humans, Immunization, Secondary, Mutation, Receptors, Virus, SARS-CoV-2, Spike Glycoprotein, Coronavirus DOWNLOADS COinS...

Oct 23, 2023 | nature.com | Yicheng Guo |Liyuan Liu |Manoj Nair |Sho Iketani |Yiming Huang |Adam S. Lauring | +3 more

AbstractA SARS-CoV-2 Omicron subvariant, BA.2.86, has emerged and spread to numerous countries worldwide, raising alarm because its spike protein contains 34 additional mutations compared to its BA.2 predecessor1. We examined its antigenicity using human sera and monoclonal antibodies (mAbs). Reassuringly, BA.2.86 was not more resistant to human sera than the currently dominant XBB.1.5 and EG.5.1, indicating that the new subvariant would not have a growth advantage in this regard.

Sep 11, 2023 | thelancet.com | Qian Wang |Columbia College |Yicheng Guo |Richard Zhang

1WHOStatement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic. These new forms have additional spike mutations that could further compromise protection mediated by antibodies elicited by previous infections, vaccinations, or both.